20 results about "Liver toxicity" patented technology

The application discloses a compound Chinese herbal medicine fermentation preparation for preventing and treating hepatotoxicity of Penaeus vannamei and a preparation method thereof. Spore bacillus is used as a fermentation strain to perform aerobic fermentation on four traditional Chinese herbal medicine stem and leaf wastes, i.e. Astragalus stem and leaf, Rhubarb stem and leaf, Codonopsis stem and leaf and Coptis stem and leaf, so as to obtain a compound Chinese herbal medicine fermentation product with higher active substances. The compound Chinese herbal medicine fermentation preparation of the application can be added into the feed of Penaeus vannamei, so as to effectively prevent and treat hepatotoxicity of Penaeus vannamei.

The present invention discloses the use of a short-term embolic agent in reducing drug accumulation in the liver, hepatic clearance and / or liver toxicity. The present invention provides the use of a short-term embolic agent in the manufacture of a medical composition for: (a) temporarily embolizing blood vessels supplying the liver; and (b) reducing the accumulation of a drug subsequently or concurrently administered intravenously in the liver. The strategy aims to minimize the exposure of a drug (such as LNP) to the liver by temporarily blocking the blood supply to the liver via the portal vein and / or arteries. The present invention significantly reduces the non-specific accumulation of a drug in the liver by temporarily blocking the portal vein, arterial and / or their branch blood flow, thereby greatly reducing the opportunity for the drug to enter the liver from a hemodynamic root.

The invention discloses a novel TNF-alpha targeted protein degradation agent for treating acute hepatic failure, the TNF-alpha targeted protein degradation agent can accurately remove excessive TNF-alpha to block a liver injury signal, and the defects that a traditional TNF-alpha inhibitor interferes tissue repair due to an overlong half-life period and an Fc fragment triggers an ADCC / CDC effect to cause drug-related hepatotoxicity are overcome. The pharmaceutical safety is improved while the treatment effectiveness is ensured, a better treatment choice is provided for acute hepatic failure and other TNF-alpha related diseases, and the pharmaceutical composition has a good clinical application prospect and an important conversion value.

Methods and uses are disclosed for treating a subject suffering from a disorder selected from a liver disorder, Cushing's syndrome, or Cushing's Disease, cancer, an infection, an inflammatory condition, a cardiovascular, endocrine, or kidney disease, and combinations thereof, or other disorder for which they may be administered a drug which may cause liver toxicity, without adverse effects on the liver. Such liver disorders include fatty liver diseases are effective for reducing high levels of liver enzymes with a favorable safety profile. The methods and uses comprise administering to the subject an effective amount of a selective nonsteroidal glucocorticoid receptor modulator such as relacorilant, including methods and uses in combination with another drug, without adverse effects on liver enzyme levels, or on liver function. In embodiments, the other drug may be a drug that may cause liver toxicity, such as drugs that inhibit CYP3A enzymes, e.g., itraconazole or ketoconazole.

The application relates to the technical field of pharmaceutical preparations, and discloses an agomelatine inhalant as well as a preparation method and application thereof. The agomelatine inhalant provided by the application comprises agomelatine or a pharmaceutically acceptable salt thereof in a form capable of being inhaled or capable of being changed into a form capable of being inhaled after being excited. From the aspect of synergism, the inhalant can avoid first-pass metabolism by changing a drug administration route, significantly improve bioavailability, and realize rapid effect by directly entering blood from the lung; from the aspect of attenuation, the inhalant can greatly reduce a drug usage amount to achieve a same treatment effect as a tablet, significantly reduce occurrence of drug toxic and side reactions, and significantly reduce liver toxicity by avoiding liver metabolism.

The invention discloses a microfluidic device and a use method thereof, and relates to the technical field of microfluidics, the microfluidic device comprises a culture substrate unit, a first cell accommodating unit, a second cell accommodating unit and an interactive interface unit, the interactive interface unit is fixedly arranged between the first cell accommodating unit and the second cell accommodating unit, and the first cell accommodating unit is connected with the second cell accommodating unit. The interactive interface unit comprises a microporous structure allowing biomolecules to pass through, so that substance exchange and signal transmission between the first cell accommodating unit and the second cell accommodating unit are realized. According to the invention, an in-vitro model with high physiological correlation and accurate prediction is brought by accurately reproducing spatial tissues and dynamic microenvironments of organs, and a tissue and blood vessel interface is successfully simulated through combination of a separated co-culture structure and a dynamic fluid perfusion system, so that cells can be self-organized into a functionalized three-dimensional structure with polarity, and the functional three-dimensional structure with polarity is formed. Therefore, the sensitivity and the specificity which are far superior to those of a traditional model are realized in tests of drug hepatotoxicity and the like.

The application discloses application of a GPR120 agonist in preventing or treating intestinal-liver immunological injury induced by poultry acetochlor poisoning. According to the intestinal-liver toxicity of chicken acetochlor, the normal expression of G protein-coupled receptor 120 is mainly changed. Subsequently, programmed cell death occurs in the intestinal tract and the liver, and a large amount of inflammatory factor release is caused; the intestinal-liver axis immunological injury is improved by activating the G protein-coupled receptor 120 in vivo and in vitro, so as to rescue the chicken acetochlor poisoning reaction. The application provides a prevention and treatment basis for poultry acetochlor poisoning immunological injury diseases, provides medical data for developing poultry immunological activity drugs or supplements, and also provides more technical means for developing and utilizing environment-friendly, efficient, targeted and slow-release new veterinary drug preparations.

The present application relates to a kind of in vitro 3D liver model and enterohepatic co-culture model and its establishment method and application, belong to the technical field of drug evaluation.The method includes the following steps: cell culture: HepaRG cell and human hepatic stellate cell are respectively carried out cell culture, standby;Cell induction: the above-mentioned HepaRG cell is seeded in culture flask and is carried out cell culture, after HepaRG cell adherent growth reaches predetermined quantity, it is replaced with induction medium and is carried out induction culture, and the induced HepaRG cell is obtained, standby;Model construction: the induced HepaRG cell and human hepatic stellate cell are made into mixed cell suspension, seed on predetermined carrier, culture, obtain the microtissue with the three-dimensional structure of liver nodule, i.e. 3D liver model.The model has the three-dimensional structure of liver nodule microtissue of liver, can well simulate the actual physiological condition of in-vivo liver, to accurately predict the liver toxicity of drug.

The present invention relates to a formulation in particular an oral formulation for the prophylaxis and treatment of TG2-related disorders like fibrosis in particular diabetic nephropathy and / or diabetic associated non-alcoholic steatohepatitis (NASH) and / or non-alcoholic steatohepatitis, and its use in the prophylaxis and / or treatment of fibrosis in particular nephropathy, NASH, idiopathic pulmonary fibrosis, and cystic fibrosis. Further, the present application relates also to the use of (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate as hepatoprotectant, i.e. as hepatoprotective agent. In addition the present invention relates to a pharmaceutical composition comprising (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate for use as hepatoprotective agent and for use in the protection of the liver against liver toxicity, the improvement of liver function, and / or in the prophylaxis or treatment of a liver disease or liver disorder.

This invention belongs to the field of natural product extraction and biomedicine technology, and discloses a carrageenan polysaccharide ATSP-1 derived from Taxus chinensis and its applications. This polysaccharide, obtained through hot water extraction and purification, has a triple helix conformation, is mainly composed of galactose, has a weight-average molecular weight of 725.95 kDa, and its backbone contains specific glycosidic bonds and differentiated sulfation patterns. ATSP-1 can upregulate the expression of MHC-I / II molecules in colonic tissue through the antigen presentation signaling pathway, thereby activating CD4+. + / CD8 + It induces specific immune responses mediated by T cells; simultaneously activates the p53 apoptosis pathway, induces tumor cell apoptosis, achieves a tumor inhibition rate of 43.14%, and has no significant liver toxicity. It can be used to prepare immune-related anti-tumor products and provides natural active polysaccharide resources.

The present invention relates to a novel coronavirus recombinant spike protein, a polynucleotide encoding the same, a vector comprising the polynucleotide, and a vaccine for preventing or treating coronavirus infection, comprising the vector. The coronavirus recombinant spike protein of the present invention is stable and thereby not easily decomposed in cells, and effectively activates immune cells thereby resulting in a high antibody production amount and T cell reactivity. It was confirmed that the vector of the present invention exhibits a high antigen expression level and thereby has a high antibody production amount and T cell reactivity, has a long antibody production period and expression period, and does not show liver toxicity. Accordingly, the vector of the present invention can be helpfully used as a vaccine for preventing or treating coronavirus infection.

The invention discloses an in-vitro hepatotoxic drug screening method based on a high-throughput plug-in chip, and belongs to the technical field of plug-in chip drug toxicity screening. According to the method, a high-throughput plug-in chip is composed of a pore plate layer, a channel layer and a plug-in; every three holes form a chip unit, separation and material exchange between the pore plate layer and the channel layer are carried out through the porous membrane on the plug-in, and gravity flow is provided through the swing table; the chip hole pitch accords with the specification of a commercial pore plate, and is compatible with various analytical instruments. Through liver chip model construction, drug incubation testing and data processing analysis, efficient hepatotoxicity drug screening is realized. According to the invention, the human adult stem cell-derived liver organs are used for establishing the chip model, and the physiological correlation of the cells is strong; compared with a mouse model, human physiological liver parenchyma characteristics can be better simulated; the operation is simple and the consumed time is short. The method realizes high-efficiency and high-reproducibility drug screening, and plays a great role in the fields of basic research, transformation application and the like of preclinical tests of drugs.

The present application relates to a kind of testosterone microcrystal, freeze-dried powder injection, suspension and its preparation method.The particle size range of testosterone microcrystal meets: D90≤20 μm.Testosterone microcrystal freeze-dried powder injection includes testosterone microcrystal, suspending agent and freeze-drying protective agent;The mass ratio of the suspending agent and the mass of the testosterone microcrystal meets (0.3-2):1.The particle size range of the testosterone microcrystal meets: D90≤20 μm.Testosterone microcrystal suspension includes water, testosterone microcrystal, suspending agent and freeze-drying protective agent;The concentration of the suspending agent is 0.3%-2%.The preparation of testosterone microcrystal prepared in the present application is short-acting preparation, has the advantages of small liver toxicity, dose accuracy and easy to use.

The invention belongs to the technical field of natural product extraction and biological medicine, and discloses carrageenan polysaccharide ATSP-1 derived from sea asparagi and application of the carrageenan polysaccharide ATSP-1. The polysaccharide is obtained through hot water extraction, separation and purification, has triple helix conformation, is mainly composed of galactose and has the weight-average molecular weight of 725.95 kDa, and a framework contains specific glucosidic bond connection and differential sulfation modes. The ATSP-1 can up-regulate the expression of MHC-I / II molecules in colon tissues through an antigen presentation signal channel, so as to activate CD4 < + > / CD8 < + > T cell mediated specific immune response; meanwhile, a p53 apoptosis pathway is activated, tumor cell apoptosis is induced, the tumor inhibition rate reaches 43.14%, no obvious hepatotoxicity exists, the polysaccharide can be used for preparing immune-related anti-tumor products, and a natural active polysaccharide resource is provided.

The disclosure relates to formulations and methods for the in chemico testing of toxins based on a discovery that measuring a reduction in enzyme activity can be used to predict in vivo toxicity, including for example, a skin corrosion, skin irritation, eye corrosion, eye irritation, lung toxicity, liver toxicity, nervous system toxicity, developmental toxicity, acute toxicity etc. Disclosed methods are rapid, easy to perform and shelf-stable approaches for identification of toxic chemicals and materials.

The application discloses application of a copper-containing compound in preparation of a medicine for preventing and / or treating obesity and related metabolic diseases. The application breaks through the traditional cognition on safety of high-dose copper, and proves that oral administration of the copper-containing compound (such as copper chloride) in a specific dose range (calculated according to copper element, such as 0.07-2.84 mg / kg body weight per day) can effectively inhibit weight growth of animals induced by a high-fat diet, and simultaneously has an effect on liver steatosis and body composition, without risk of liver toxicity. Compared with existing weight loss methods, the application scheme has the advantages of low raw material price, convenient oral use, wide safety window, remarkable comprehensive effect and the like, and provides a clear direction and a solid experimental basis for development of a new, economical and safe medicine or health care food for preventing and treating obesity.

The present application relates to the use of platelet factor 4 in the preparation of a drug for treating or preventing Candida albicans infection, platelet factor 4 acts on macrophage CXCR3 receptor, antagonizes Candida albicans induced macrophage PANoptosis, thereby reducing the damage of Candida albicans to macrophages, maintaining the survival and normal function of macrophages, enhancing the clearance ability of the body to Candida albicans, reducing the inflammatory response caused by infection, reducing pathological damage, and different from the treatment mechanism of traditional antifungal drugs, the present application does not directly act on fungi, which helps to reduce the formation of drug-resistant strains and the toxic side effects such as liver toxicity and kidney toxicity caused by antifungal drugs, and can provide a more optimal new treatment mode for clinical Candida albicans infection.

The application discloses a Simiao pill compound fermentation liquor and a preparation method and application thereof, and comprises the following steps: taking a mixture of Radix Cyathulae, Coicis Semen, Atractylodis Rhizome and Cortex Phellodendri powder according to a preset proportion; preparing a liquid culture medium; adding the powder mixture into the liquid culture medium to obtain a fermentation base, and cooling after high-temperature cooking; inoculating Lactobacillus on the fermentation base to start fermentation culture; terminating the fermentation at high temperature; filtering, centrifuging, taking supernatant to obtain the Simiao pill compound fermentation liquor, and the fermentation liquor can be used for reducing the uric acid level of human body. The in-vivo research results of mice show that the Simiao pill compound fermentation liquor is superior to the unfermented Simiao pill compound in the effects of reducing uric acid and protecting kidney, and the high-dose group of the fermented Simiao pill can effectively reduce the uric acid level in the body of hyperuricemia mice and play a role in protecting the kidney; the liver toxicity experiment results show that the fermented Simiao pill compound does not produce toxicity to the liver of mice.

The invention discloses application of humic acid in preparation of a product for relieving toxicity of MXene nanosheets to fish and remediation of a polluted water body, humic acid is added into a feeding water body which is used for feeding fish and contains Ti3C2 MXene nanosheets, and then morphological changes of intestinal tissues of adult zebra fish are observed through histopathologic sections; the damage degree of the Ti3C2 MXene nanosheet to the intestinal tract of the adult zebra fish is judged, and meanwhile, the expression of intestinal inflammatory factor correlators, the related indexes of intestinal tissue oxidative stress and the related indexes of liver tissue oxidative stress and inflammatory factors are detected. The application proves that the humic acid can effectively relieve the damage of the Ti3C2 MXene nanosheet to the intestinal tract of the adult zebra fish and the interference of the Ti3C2 MXene nanosheet to the intestinal-hepatic axis, reduces the hepatotoxicity caused by the Ti3C2 MXene nanosheet, and provides theoretical guidance for the subsequent development of a nano-material toxicity alleviator for adult aquatic organisms and the repair of a nano-material polluted water body.